Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease

AIMS: REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Sammons, E, Hopewell, J C, Chen, F, Stevens, W, Wallendszus, K, Valdes-Marquez, E, Dayanandan, R, Knott, C, Murphy, K, Wincott, E, Baxter, A, Goodenough, R, Lay, M, Hill, M, Macdonnell, S, Fabbri, G, Lucci, D, Fajardo-Moser, M, Brenner, S, Hao, D, Zhang, H, Liu, J, Wuhan, B, Mosegaard, S, Herrington, W, Wanner, C, Angermann, C, Ertl, G, Maggioni, A, Barter, P, Mihaylova, B, Mitchel, Y, Blaustein, R, Goto, S, Tobert, J, DeLucca, P, Chen, Y, Chen, Z, Gray, A, Haynes, R, Armitage, J, Baigent, C, Wiviott, S, Cannon, C, Braunwald, E, Collins, R, Bowman, L, Landray, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986460/
https://www.ncbi.nlm.nih.gov/pubmed/34910136
http://dx.doi.org/10.1093/eurheartj/ehab863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986460/
https://www.ncbi.nlm.nih.gov/pubmed/34910136
http://dx.doi.org/10.1093/eurheartj/ehab863

Ejemplares similares